Johnson & Johnson Stock Price, News & Analysis

Johnson & Johnson (NYSE:JNJ) has submitted a supplemental Biologics License Application (sBLA) to the FDA for TREMFYA® (guselkumab) seeking to include new evidence of joint structural damage inhibition in active psoriatic arthritis (PsA) patients.

The submission is supported by the Phase 3b APEX study, which achieved its primary endpoint of reducing joint symptoms (ACR20) and secondary endpoint of inhibiting structural damage progression at 24 weeks. TREMFYA® would become the first and only IL-23 inhibitor proven to both control symptoms and significantly inhibit joint damage progression in active PsA.

As a dual-acting monoclonal antibody, TREMFYA® uniquely blocks IL-23 while binding to CD64, demonstrating a well-established safety profile in the study.

Johnson & Johnson (NYSE: JNJ) announced its participation in the upcoming 2025 Wells Fargo Healthcare Conference. The company's management will engage in a Fireside Chat on September 3rd, 2025, at 11:50 a.m. Eastern Time.

Investors can access the live audio webcast through JNJ's Investor Relations website. An archived version will be available approximately 48 hours after the presentation.

Johnson & Johnson (NYSE:JNJ) will present significant advancements in Alzheimer's disease research at the Alzheimer's Association International Conference (AAIC) from July 27-31, 2025, in Toronto. The company will showcase 12 research abstracts focusing on tau's impact on brain function in early Alzheimer's and the predictive capabilities of plasma biomarker pTau217.

A key highlight includes new findings from the Global Neurodegeneration Proteomics Consortium (GNPC), a partnership between J&J and Gates Ventures, representing the world's largest neurodegenerative disease proteomics resource. The research spans various areas, including tau PET imaging, CSF proteomics, plasma biomarkers, and AI-based diagnostic approaches.

Johnson & Johnson (NYSE:JNJ) has submitted a New Drug Application (NDA) to the FDA for icotrokinra, a first-in-class targeted oral peptide for treating moderate to severe plaque psoriasis in adults and patients 12+ years old. The submission includes data from four Phase 3 studies (ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 & 2) where icotrokinra met all primary endpoints.

The drug demonstrated superior efficacy to deucravacitinib and showed promising results in difficult-to-treat areas. Safety data revealed similar adverse events between icotrokinra (49.1%) and placebo (51.9%). The company has also initiated ICONIC-ASCEND, the first head-to-head study comparing an oral pill (icotrokinra) to an injectable biologic (ustekinumab).

Johnson & Johnson (NYSE: JNJ) announced that the FDA has granted Priority Review for TAR-200, an innovative intravesical drug releasing system for treating high-risk non-muscle invasive bladder cancer (HR-NMIBC) in patients who are unresponsive to BCG therapy.

The Phase 2b SunRISe-1 study demonstrated impressive results with an 82.4% complete response rate, and 52.9% of patients remaining cancer-free for at least one year. TAR-200 represents the first significant innovation in bladder cancer drug delivery in over 40 years, providing sustained local treatment delivery over three weeks per cycle.

The treatment can be administered in an outpatient setting in under five minutes, requiring no general anesthesia or additional monitoring.

Dean Omar Branham Shirley trial attorney Aaron Chapman has been recognized in the 2025 Lawdragon 500 X – The Next Generation legal guide for his work in plaintiff litigation. Chapman was part of a trial team that secured an $8 million verdict against Johnson & Johnson (NYSE: JNJ) in Suffolk County, Mass., representing a woman who developed mesothelioma from talcum powder products.

The attorney has notable experience in asbestos litigation across multiple states and previously helped secure the largest asbestos-related personal injury verdict in Nevada in 2021. The recognition by Lawdragon highlights emerging legal leaders selected through nominations, research, and peer recommendations.

Johnson & Johnson (NYSE: JNJ) has announced its quarterly dividend for Q3 2025. The company's Board of Directors has declared a cash dividend of $1.30 per share on its common stock. The dividend will be paid on September 9, 2025 to shareholders of record as of August 26, 2025, which is also the ex-dividend date.

Johnson & Johnson (NYSE: JNJ) reported strong Q2 2025 results with reported sales growth of 5.8% to $23.7 billion and adjusted EPS of $2.77. The company raised its 2025 guidance, increasing estimated reported sales by $2 billion to 5.4% growth and adjusted EPS to $10.85 at midpoint.

Performance was driven by growth in both segments: Innovative Medicine sales grew 3.8% operationally, led by DARZALEX, CARVYKTI, and TREMFYA, while MedTech sales increased 6.1% operationally, with strong performance in cardiovascular and general surgery products.

Notable achievements include FDA approval of IMAAVY for generalized myasthenia gravis, priority review for TAR-200, and positive CARVYKTI data in multiple myeloma. The company anticipates significant pipeline progress in H2 2025 across multiple therapeutic areas.

Johnson & Johnson (NYSE:JNJ) has submitted a supplemental New Drug Application (sNDA) to the FDA for CAPLYTA® (lumateperone) based on impressive Phase 3 trial results in schizophrenia relapse prevention. The study demonstrated a 63% reduction in relapse risk compared to placebo, with significantly longer time to relapse during the 26-week double-blind treatment phase (p=0.0002).

The trial's safety profile remained consistent with existing clinical data, with headache being the most common adverse event. CAPLYTA® is already FDA-approved for schizophrenia treatment and is the first approved therapy for both bipolar I and II depression. The drug's mechanism involves high serotonin 5-HT2A receptor occupancy and lower dopamine D2 receptor occupancy at therapeutic doses.